229 related articles for article (PubMed ID: 33071281)
1. Differential sensitivity of acute myeloid leukemia cells to daunorubicin depends on P2X7A versus P2X7B receptor expression.
Pegoraro A; Orioli E; De Marchi E; Salvestrini V; Milani A; Di Virgilio F; Curti A; Adinolfi E
Cell Death Dis; 2020 Oct; 11(10):876. PubMed ID: 33071281
[TBL] [Abstract][Full Text] [Related]
2. Trophic activity of human P2X7 receptor isoforms A and B in osteosarcoma.
Giuliani AL; Colognesi D; Ricco T; Roncato C; Capece M; Amoroso F; Wang QG; De Marchi E; Gartland A; Di Virgilio F; Adinolfi E
PLoS One; 2014; 9(9):e107224. PubMed ID: 25226385
[TBL] [Abstract][Full Text] [Related]
3. LEDGF/p75 has increased expression in blasts from chemotherapy-resistant human acute myelogenic leukemia patients and protects leukemia cells from apoptosis in vitro.
Huang TS; Myklebust LM; Kjarland E; Gjertsen BT; Pendino F; Bruserud Ø; Døskeland SO; Lillehaug JR
Mol Cancer; 2007 Apr; 6():31. PubMed ID: 17451600
[TBL] [Abstract][Full Text] [Related]
4. Targeted inhibition of ULK1 enhances daunorubicin sensitivity in acute myeloid leukemia.
Qiu L; Zhou G; Cao S
Life Sci; 2020 Feb; 243():117234. PubMed ID: 31887299
[TBL] [Abstract][Full Text] [Related]
5. CALCRL induces resistance to daunorubicin in acute myeloid leukemia cells through upregulation of XRCC5/TYK2/JAK1 pathway.
Tang S; Li S; Shi X; Sheng L; Mu Q; Wang Y; Zhu H; Xu K; Zhou M; Xu Z; Wu A; Ouyang G
Anticancer Drugs; 2024 Feb; 35(2):163-176. PubMed ID: 37948318
[TBL] [Abstract][Full Text] [Related]
6. Daunorubicin-Loaded CdTe QDs Conjugated with Anti-CD123 mAbs: A Novel Delivery System for Myelodysplastic Syndromes Treatment.
Guo D; Xu P; Chen D; Wang L; Zhu Y; Zuo Y; Chen B
Int J Nanomedicine; 2020; 15():521-536. PubMed ID: 32021192
[TBL] [Abstract][Full Text] [Related]
7. Role of NF-E2 related factor 2 (Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML) and the effect of pharmacological inhibition of Nrf2.
Karathedath S; Rajamani BM; Musheer Aalam SM; Abraham A; Varatharajan S; Krishnamurthy P; Mathews V; Velayudhan SR; Balasubramanian P
PLoS One; 2017; 12(5):e0177227. PubMed ID: 28505160
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia.
Ross DD; Wooten PJ; Sridhara R; Ordóñez JV; Lee EJ; Schiffer CA
Blood; 1993 Aug; 82(4):1288-99. PubMed ID: 8102561
[TBL] [Abstract][Full Text] [Related]
9. Daunorubicin-containing CLL1-targeting nanomicelles have anti-leukemia stem cell activity in acute myeloid leukemia.
Lin TY; Zhu Y; Li Y; Zhang H; Ma AH; Long Q; Keck J; Lam KS; Pan CX; Jonas BA
Nanomedicine; 2019 Aug; 20():102004. PubMed ID: 31055076
[TBL] [Abstract][Full Text] [Related]
10. Effect of the protein kinase C inhibitor staurosporine on chemosensitivity to daunorubicin of normal and leukemic fresh myeloid cells.
Laredo J; Huynh A; Muller C; Jaffrézou JP; Bailly JD; Cassar G; Laurent G; Demur C
Blood; 1994 Jul; 84(1):229-37. PubMed ID: 7912555
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
[TBL] [Abstract][Full Text] [Related]
12. HMGA2 regulates acute myeloid leukemia progression and sensitivity to daunorubicin via Wnt/β-catenin signaling.
Yang S; Gu Y; Wang G; Hu Q; Chen S; Wang Y; Zhao M
Int J Mol Med; 2019 Aug; 44(2):427-436. PubMed ID: 31173171
[TBL] [Abstract][Full Text] [Related]
13. Daunorubicin and Cytarabine Liposome in Newly Diagnosed Therapy-Related Acute Myeloid Leukemia (AML) or AML With Myelodysplasia-Related Changes.
Kim M; Williams S
Ann Pharmacother; 2018 Aug; 52(8):792-800. PubMed ID: 29532662
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of Daunorubicin in adult patients with acute myeloid leukemia.
Varatharajan S; Panetta JC; Abraham A; Karathedath S; Mohanan E; Lakshmi KM; Arthur N; Srivastava VM; Nemani S; George B; Srivastava A; Mathews V; Balasubramanian P
Cancer Chemother Pharmacol; 2016 Nov; 78(5):1051-1058. PubMed ID: 27738808
[TBL] [Abstract][Full Text] [Related]
15. Extracellular ATP induces apoptosis through P2X7R activation in acute myeloid leukemia cells but not in normal hematopoietic stem cells.
Salvestrini V; Orecchioni S; Talarico G; Reggiani F; Mazzetti C; Bertolini F; Orioli E; Adinolfi E; Di Virgilio F; Pezzi A; Cavo M; Lemoli RM; Curti A
Oncotarget; 2017 Jan; 8(4):5895-5908. PubMed ID: 27980223
[TBL] [Abstract][Full Text] [Related]
16. Leukotrienes promote stem cell self-renewal and chemoresistance in acute myeloid leukemia.
Stranahan AW; Berezniuk I; Chakraborty S; Feller F; Khalaj M; Park CY
Leukemia; 2022 Jun; 36(6):1575-1584. PubMed ID: 35461365
[TBL] [Abstract][Full Text] [Related]
17. Lack of correlation between expression and function of P-glycoprotein in acute myeloid leukemia cell lines.
Bailly JD; Muller C; Jaffrézou JP; Demur C; Gassar G; Bordier C; Laurent G
Leukemia; 1995 May; 9(5):799-807. PubMed ID: 7769842
[TBL] [Abstract][Full Text] [Related]
18. A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.
Cortes J; Kantarjian H; Albitar M; Thomas D; Faderl S; Koller C; Garcia-Manero G; Giles F; Andreeff M; O'Brien S; Keating M; Estey E
Cancer; 2003 Mar; 97(5):1234-41. PubMed ID: 12599230
[TBL] [Abstract][Full Text] [Related]
19. Equipotent doses of daunorubicin and idarubicin for AML: a meta-analysis of clinical trials versus in vitro estimation.
Adige S; Lapidus RG; Carter-Cooper BA; Duffy A; Patzke C; Law JY; Baer MR; Ambulos NP; Zou Y; Bentzen SM; Emadi A
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1105-1112. PubMed ID: 30968179
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-33b regulates sensitivity to daunorubicin in acute myelocytic leukemia by regulating eukaryotic translation initiation factor 5A-2.
Liu Y; Lei P; Qiao H; Sun K; Lu X; Bao F; Yu R; Lian C; Li Y; Chen W; Xue F
J Cell Biochem; 2020 Jan; 121(1):385-393. PubMed ID: 31222822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
